Welcome to our dedicated page for Biolinerx SEC filings (Ticker: BLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioLineRx Ltd. filings document the regulatory record of a foreign private issuer focused on oncology and rare-disease drug development. Recent Form 6-K reports include financial results, interim consolidated financial statements, operating and financial reviews, and press-release exhibits incorporated by reference into effective Securities Act registration statements.
The filings also record company-specific matters such as the GLIX1 collaboration and joint-venture agreements with Hemispherian, GLIX1 patent and clinical-development disclosures, motixafortide and APHEXDA commercial context, and a final arbitration award involving the motixafortide in-licensing agreement. These disclosures frame BioLineRx's business updates, capital commitments, intellectual-property position, legal contingencies, and governance authorization as a Nasdaq- and TASE-listed issuer.
BioLineRx Ltd. filed a Form 6-K to report that it has issued a press release announcing a USPTO Notice of Allowance for a key patent covering its GLIX1 candidate for treating a broad range of cancer types. This step means the U.S. patent office has indicated it intends to grant the patent, strengthening BioLineRx’s intellectual property position around GLIX1 and its potential oncology uses.
BioLineRx Ltd. has entered into a new joint venture with Norwegian company Hemispherian AS to develop, test, and commercialize GLIX1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma and other solid tumors. A new company has been formed, initially owned 60% by Hemispherian and 40% by BioLineRx.
Hemispherian transferred GLIX1-related intellectual property, regulatory filings, know-how, and associated assets to the joint venture. In return, BioLineRx committed to invest $5 million over up to 42 months under a staged development plan, with the risk that any unfunded portion could lead to a proportional repurchase of its stake for nominal consideration. BioLineRx can later increase its ownership up to 70% through additional investments, while Hemispherian may co-invest to maintain 50% once BioLineRx reaches that level.
BioLineRx will manage the joint venture’s operations and budget, while the joint venture will pay Hemispherian a monthly advisory fee of $80,000 for 24 months or until termination. Governance is shared through a board and steering committee where BioLineRx holds the deciding vote in deadlocks, and the joint venture receives first look and first refusal rights on other Hemispherian pipeline assets.
Highbridge Capital Management disclosed a 7.2% position in BioLineRx Ltd. represented by 172,950,600 Ordinary Shares assuming exercise of warrants held by Highbridge Funds. The filing states these shares are represented by 288,251 ADSs issuable upon exercise of warrants and that each ADS represents 600 Ordinary Shares. Highbridge reports sole voting and dispositive power over the 172,950,600 Ordinary Shares. The percentage is calculated using an outstanding share base of 2,232,601,990 Ordinary Shares as reported by the issuer.
BioLineRx Ltd. filed a Form 6-K as a foreign private issuer for August 2025, reporting that it has released its financial results for the three and six months ended June 30, 2025. The submission includes a press release, unaudited condensed consolidated interim financial statements, and an operating and financial review for that period. These materials are incorporated by reference into all of the company’s effective registration statements under the Securities Act of 1933, meaning those registration statements now formally include the newly reported interim financial information.